Skip to content

GEBT Lot-to-Lot and Biological Variability

13C-Spirulina Breath Test (13C-GEBT) Lot-to-Lot and Biological Variability Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04772261
Enrollment
21
Registered
2021-02-26
Start date
2021-02-05
Completion date
2022-01-10
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroparesis

Keywords

Gastroenterology, Gastric emptying breath test

Brief summary

The purpose of this study is to collect information regarding lot-to-lot variability in 13C-Spirulina test meal lets and within-subject biological variability.

Detailed description

In this study participants will participate in one or two arms of the study. In one arm the participants will be administered GEBT tests that contain different 13C-Spirulina/Egg mix drug lots. In the second arm, the participants will be administered GEBT tests from the same 13C-Spirulina/Egg mix drug lot. All GEBT kit lots will be administered according to the FDA-approved labeling.

Interventions

DIAGNOSTIC_TEST13C-Spirulina GEBT

Various lots of 13C-Spirulina GEBT test meals

Sponsors

Cairn Diagnostics
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Males and females, 18-85 years old at time of signing the informed consent form * Ability to eat test meal and provide breath samples

Exclusion criteria

* History or physical exam suggestive of systemic disease such as diabetes mellitus or pathophysiologic disorders such as renal failure, chronic heart disease, chronic respiratory disease, liver disease, or malabsorption. * History of abdominal surgery except appendectomy * Use of any medications that may alter gastric motility within two days of the study * Use of narcotics or anticholinergics within two days of the study * Females on hormone replacement therapy other than birth control medications * Pregnancy * Intolerance or allergy to any component of GEBT test meal * History of neurologic or psychiatric disorders

Design outcomes

Primary

MeasureTime frameDescription
Lot to Lot Variabilityup to 3 monthsParticipant kPCD values at each measured timepoint from each lot of 13C-Spirulina GEBT test meal will be plotted to compare in vivo results across each lot of material
Biological VariabilityUp to 3 monthsParticipant kPCD values at each measured timepoint from the same 13C-Spirulina GEBT test meal will be plotted to compare against each other

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026